Equities

QuidelOrtho Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert

QuidelOrtho Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)23.58
  • Today's Change-0.155 / -0.65%
  • Shares traded390.00
  • 1 Year change-43.39%
  • Beta0.7445
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

QuidelOrtho Corporation provides in vitro diagnostics, developing and manufacturing intelligent solutions. The Company specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.

  • Revenue in USD (TTM)2.73bn
  • Net income in USD-1.13bn
  • Incorporated2021
  • Employees6.60k
  • Location
    QuidelOrtho Corp9975 Summers Ridge RoadSAN DIEGO 92121United StatesUSA
  • Phone+1 (858) 552-1100
  • Fax+1 (858) 453-4338
  • Websitehttps://www.quidelortho.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Enovis Corp2.23bn-1.37bn1.25bn7.37k--0.6161--0.5575-24.20-24.2039.3535.330.44741.565.37303,144.60-27.38-3.14-30.81-3.5657.1952.01-61.19-9.771.160.04950.4018--23.46-8.73-1,423.10--7.58--
Iradimed Corp83.81m22.48m1.27bn160.0057.0613.4275.4715.151.751.756.527.440.8094------21.7118.0623.8620.2176.7576.8526.8225.51--------14.4321.4516.88108.61----
Tandem Diabetes Care Inc1.01bn-203.37m1.28bn2.65k--9.66--1.28-3.05-3.0515.081.961.103.258.64380,000.40-22.20-10.11-30.80-12.3353.2351.67-20.20-11.711.90-9.880.7028--25.7421.0156.86--27.42--
Conmed Corp1.37bn47.06m1.29bn3.90k27.59--10.670.94161.521.5244.24------------------54.0855.563.423.78--3.24----5.189.77-64.4737.66---5.59
Adapthealth Corp3.26bn75.81m1.38bn10.50k18.370.85442.900.42430.55530.555323.9011.940.735417.208.33310,020.301.96-2.812.28-3.1725.3219.632.67-4.190.85842.300.5253--1.9043.84112.19--70.36--
Procept Biorobotics Corp299.91m-84.58m1.55bn756.00--4.08--5.18-1.54-1.545.456.810.67721.813.91396,702.40-19.10-26.94-21.74-29.8164.5554.37-28.20-83.147.20--0.1194--64.84105.2113.68---10.34--
Pulse Biosciences Inc86.00k-74.73m1.56bn75.00--16.82--18,131.77-1.14-1.140.00131.370.0009----1,146.67-74.06-83.75-80.63-94.40-224.42---86,898.84-12,644.5210.01--0.00-------26.95---27.12--
Kestra Medical Technologies Ltd74.26m-138.79m1.57bn330.00--8.44--21.15-2.76-2.761.473.190.4034--9.40225,027.30-71.43-122.23-92.37-192.3546.40---177.06-342.51---116.720.2033--115.05---25.08--150.61--
Quidelortho Corp2.73bn-1.13bn1.60bn6.60k--0.8341--0.5867-16.66-16.6640.2728.270.44782.627.46---18.56-6.45-22.13-7.3946.6753.89-41.45-14.400.90020.67570.5798---1.8910.4444.84------
AtriCure Inc518.31m-28.77m1.62bn1.30k--3.41--3.13-0.608-0.60810.909.590.8291.688.79398,696.20-4.60-3.84-5.24-4.2574.8774.53-5.55-7.132.85-17.960.1252--16.5515.05-46.85--14.00--
Omnicell Inc1.18bn2.05m1.64bn3.60k844.321.3320.011.380.04320.043225.7027.450.57867.195.01--0.10020.73310.13570.976742.4944.800.17321.321.22--0.1198--6.535.84-83.62-42.341.93--
AxoGen Inc214.71m-2.10m1.67bn451.00--12.69343.247.76-0.0486-0.04864.562.621.051.557.75476,073.20-1.03-11.36-1.17-13.0574.7678.42-0.9767-15.372.640.64930.2852--17.8111.9154.12---2.84--
Inspire Medical Systems Inc911.98m145.42m1.71bn1.33k12.022.1910.711.874.974.9730.7527.331.061.188.57684,156.8016.953.0919.003.4885.3984.8315.953.054.56--0.000.0013.6051.21171.77--73.41--
Artivion Inc422.65m-9.12m1.75bn1.60k--3.95126.384.14-0.242-0.2429.489.260.5091.725.16264,153.80-1.10-2.47-1.29-2.6664.5065.02-2.16-5.892.881.290.3324--9.757.0656.37--6.75--
Heartflow Inc-100.00bn-100.00bn1.76bn699.00--6.77----------3.05----------------------------0.00--44.32--22.04------
UFP Technologies Inc597.95m67.12m1.90bn4.15k28.544.6922.063.178.618.6176.7152.370.92614.896.86144,223.8010.4010.1211.8711.5328.5127.0711.2310.641.368.390.26570.0026.0820.5231.2924.4610.82--
Data as of Feb 13 2026. Currency figures normalised to QuidelOrtho Corp's reporting currency: US Dollar USD

Institutional shareholders

71.80%Per cent of shares held by top holders
HolderShares% Held
T. Rowe Price Investment Management, Inc.as of 30 Sep 202511.01m16.22%
BlackRock Fund Advisorsas of 31 Dec 20259.46m13.93%
The Vanguard Group, Inc.as of 31 Dec 20257.00m10.31%
Fidelity Management & Research Co. LLCas of 30 Sep 20254.44m6.54%
Rubric Capital Management LPas of 31 Dec 20253.78m5.56%
Dimensional Fund Advisors LPas of 31 Dec 20252.73m4.03%
SSgA Funds Management, Inc.as of 31 Dec 20252.70m3.98%
Newtyn Management LLCas of 30 Sep 20252.70m3.98%
Invesco Advisers, Inc.as of 30 Sep 20252.61m3.84%
American Century Investment Management, Inc.as of 31 Dec 20252.33m3.43%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.